Galiza Soares J, Sutley-Koury S, Pomrenze M, Tucciarone J
Front Neuroanat. 2025; 18:1521016.
PMID: 39917739
PMC: 11798945.
DOI: 10.3389/fnana.2024.1521016.
Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan V, Zaveri N
Addict Biol. 2017; 23(2):585-595.
PMID: 28635181
PMC: 5740020.
DOI: 10.1111/adb.12513.
Carlezon Jr W, Krystal A
Depress Anxiety. 2016; 33(10):895-906.
PMID: 27699938
PMC: 5288841.
DOI: 10.1002/da.22500.
Kohut S, Fivel P, Mello N
Drug Alcohol Depend. 2013; 133(2):593-9.
PMID: 23998378
PMC: 3818349.
DOI: 10.1016/j.drugalcdep.2013.07.032.
Carroll F, Carlezon Jr W
J Med Chem. 2013; 56(6):2178-95.
PMID: 23360448
PMC: 3612131.
DOI: 10.1021/jm301783x.
Buprenorphine modulates methamphetamine-induced dopamine dynamics in the rat caudate nucleus.
Pereira F, Gough B, Macedo T, Ribeiro C, Ali S, Binienda Z
Neurotox Res. 2009; 19(1):94-101.
PMID: 20033362
DOI: 10.1007/s12640-009-9143-9.
Opioid receptors and myocardial protection: do opioid agonists possess cardioprotective effects?.
McCormack K, Chapleo C
Clin Drug Investig. 2008; 15(5):445-54.
PMID: 18370500
DOI: 10.2165/00044011-199815050-00009.
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.
Kleber H
Dialogues Clin Neurosci. 2008; 9(4):455-70.
PMID: 18286804
PMC: 3202507.
Therapeutic options and challenges for substances of abuse.
Gardner T, Kosten T
Dialogues Clin Neurosci. 2008; 9(4):431-45.
PMID: 18286802
PMC: 3202509.
Buprenorphine-containing treatments: place in the management of opioid addiction.
Robinson S
CNS Drugs. 2006; 20(9):697-712.
PMID: 16953647
DOI: 10.2165/00023210-200620090-00001.
EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES.
Mello N
NIDA Res Monogr. 2006; 185:82-104.
PMID: 16906230
PMC: 1538975.
Influence of psychotherapy attendance on buprenorphine treatment outcome.
Montoya I, Schroeder J, Preston K, Covi L, Umbricht A, Contoreggi C
J Subst Abuse Treat. 2005; 28(3):247-54.
PMID: 15857725
PMC: 2633651.
DOI: 10.1016/j.jsat.2005.01.004.
Treating cocaine addiction with viruses.
Carrera M, Kaufmann G, Mee J, Meijler M, Koob G, Janda K
Proc Natl Acad Sci U S A. 2004; 101(28):10416-21.
PMID: 15226496
PMC: 478586.
DOI: 10.1073/pnas.0403795101.
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
Montoya I, Gorelick D, Preston K, Schroeder J, Umbricht A, Cheskin L
Clin Pharmacol Ther. 2004; 75(1):34-48.
PMID: 14749690
PMC: 2633656.
DOI: 10.1016/j.clpt.2003.09.004.
Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.
Robinson S
CNS Drug Rev. 2002; 8(4):377-90.
PMID: 12481193
PMC: 6741692.
DOI: 10.1111/j.1527-3458.2002.tb00235.x.
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.
Quinn D, Wodak A, Day R
Clin Pharmacokinet. 1997; 33(5):344-400.
PMID: 9391747
DOI: 10.2165/00003088-199733050-00003.
Combined effects of buprenorphine and a nondrug alternative reinforcer on i.v. cocaine self-administration in rats maintained under FR schedules.
Comer S, Lac S, Wyvell C, Carroll M
Psychopharmacology (Berl). 1996; 125(4):355-60.
PMID: 8826540
DOI: 10.1007/BF02246018.
Buprenorphine differentially alters opioid receptor adaptation in rat brain regions.
Belcheva M, Ho M, Ignatova E, Jefcoat L, Barg J, Vogel Z
J Pharmacol Exp Ther. 1996; 277(3):1322-7.
PMID: 8667193
PMC: 1805810.
Lack of involvement of delta-opioid receptors in mediating the rewarding effects of cocaine.
de Vries T, Babovic-Vuksanovic D, Elmer G, Shippenberg T
Psychopharmacology (Berl). 1995; 120(4):442-8.
PMID: 8539325
DOI: 10.1007/BF02245816.
Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.
Belcheva M, Barg J, McHale R, Dawn S, Ho M, Ignatova E
Mol Pharmacol. 1993; 44(1):173-9.
PMID: 8393519
PMC: 2516495.
